--- title: "Salubris: Aliskiren Indapamide Sustained-Release Tablets Obtained Drug Registration Certificate" type: "News" locale: "en" url: "https://longbridge.com/en/news/243075138.md" description: "According to the Zhitong Finance APP, Salubris announced that the company has received the drug registration certificate for Aliskiren Indapamide Sustained-release Tablets (Fuli'an®) approved by the National Medical Products Administration. Aliskiren Indapamide Sustained-release Tablets (Fuli'an®) are used for the treatment of primary hypertension" datetime: "2025-06-04T09:56:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/243075138.md) - [en](https://longbridge.com/en/news/243075138.md) - [zh-HK](https://longbridge.com/zh-HK/news/243075138.md) generator: "portal-rs" --- # Salubris: Aliskiren Indapamide Sustained-Release Tablets Obtained Drug Registration Certificate According to the Zhitong Finance APP, Salubris (002294.SZ) announced that the company has received the drug registration certificate for Aliskiren Indapamide Sustained-release Tablets (Fuli'an®) approved by the National Medical Products Administration. Aliskiren Indapamide Sustained-release Tablets (Fuli'an®) are used for the treatment of primary hypertension ### Related Stocks - [002294.CN](https://longbridge.com/en/quote/002294.CN.md) ## Related News & Research - [Vishnusurya Projects and Infra's (NSE:VISHNUINFR) Weak Earnings May Only Reveal A Part Of The Whole Picture](https://longbridge.com/en/news/305559929.md) - [Pondy Oxides And Chemicals Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected](https://longbridge.com/en/news/305560101.md) - [Alkem Laboratories Limited (NSE:ALKEM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates](https://longbridge.com/en/news/305559747.md) - [RioCan Real Estate Investment Trust (TSX:REI.UN) Expands Its Buyback Program, Is It Still Undervalued?](https://longbridge.com/en/news/305557624.md) - [Kava Lend loses roughly $3.8 million to hack, sending KAVA token down nearly 40%](https://longbridge.com/en/news/305556359.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**